Previous close | 3.8000 |
Open | 3.8000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 3.5000 - 3.8999 |
52-week range | 1.6000 - 4.4000 |
Volume | |
Avg. volume | 23,826 |
Market cap | 299.92M |
Beta (5Y monthly) | 0.77 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.4100 |
Earnings date | 28 Feb 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.88 |
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that two scientific presentations on the sozinibercept (OPT-302) Phase 2 clinical trial results and ongoing Phase 3 clinical trial program will be made at the Retina World C
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that Dr. Frederic Guerard, Chief Executive Officer (CEO) of Opthea, will present the Company’s clinical-stage pipeline, as well as its innovation agenda, at the OIS Retina
Key Insights Institutions' substantial holdings in Opthea implies that they have significant influence over the...